Swedish Orphan Biovitrum (SOBI) investor relations material

Strategic vision and growth outlook

• Ambition to double revenue to SEK 55 billion by 2030, targeting an adjusted EBITDA/EBITA margin in the high or upper 30s%.

• Six major product launches planned by 2028, including ALTUVIIIO/Altuvoct, Gamifant, Aspaveli, TRYNGOLZA, NASP, and pozdeutinurad, with five having blockbuster potential.

• Continued focus on rare diseases and expansion into new therapeutic areas such as gout, severe hypertriglyceridemia, and sepsis.

• Globalization strategy broadened, with direct presence in over 90% of the global rare disease market and recent expansion into Japan, Korea, Australia, Brazil, and LATAM.

• Ongoing disciplined investment and resource reallocation from mature to growth areas, with phased launches and cost discipline to smooth investment peaks.

R&D and innovation engine

• Over 40 global clinical trials ongoing, with five major approvals in the last 24 months and two additional submissions under review.

• Robust pipeline includes three phase II and five phase III assets, targeting indications such as interferon gamma-driven sepsis, VEXAS syndrome, and severe aplastic anemia.

• Strong scientific output with over 40 peer-reviewed manuscripts in 2025 and 36 regulatory approvals across major and emerging markets.

• Florio, a digital rare disease patient platform, now operates in 26 countries, supporting real-world data collection and patient engagement.

• AI and digital tools are leveraged to accelerate development cycles, improve regulatory submissions, and enhance field force effectiveness.

Product and market highlights

• ALTUVIIIO/Altuvoct is driving strong growth in Europe, with significant patient uptake, expansion into new countries, and a focus on long-term outcomes like joint health and synovitis.

• Aspaveli has shown unprecedented efficacy in nephrology, with broad regulatory approvals and ongoing global launches, targeting SEK 7-10bn peak sales.

• TRYNGOLZA (olezarsen) demonstrated significant triglyceride reduction and acute pancreatitis risk reduction in FCS and severe hypertriglyceridemia, with a focus on patients above 880 mg/dL.

• NASP and pozdeutinurad are positioned to address high unmet needs in refractory and progressive gout, with phase III data expected and potential to become first meaningful innovations in gout in 15 years.

• Gamifant is advancing in interferon gamma-driven sepsis, showing a 12% absolute mortality reduction in phase IIa, with plans for pivotal trials and potential for blockbuster sales.